<DOC>
	<DOC>NCT01312324</DOC>
	<brief_summary>We try to evaluate whether neoadjuvant docetaxel plus cisplatin can increase the complete resection rate in advanced thymic carcinoma.</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thymus Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>histologically confirmed thymic carcinoma surgically inoperable Masaoka stage III or IV ECOG 02 at least one measurable disease previous myocardiac infarct history within 1 year before the enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>thymic cancer</keyword>
</DOC>